A novel tumor-associated protein: clinical significance of serum levels in various clinical conditions with special reference to gynecological malignant diseases
article
OA: closed
CC0
AI-generated summary
This study identified a novel tumor-associated protein and evaluated its serum levels in various clinical conditions, with a particular focus on gynecological malignancies.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
A novel tumor-associated protein (TAP), that was originally detected immunologically through the use of a monospecific antiserum against a placental antigen, was quantified by means of the rocket technique of Laurell. Four hundred and fifty-seven serum samples were obtained from healthy female subjects (55), and patients with leiomyomas (162), benign ovarian tumors (78), pelvic endometriosis (45), cervical cancer (73), endometrial cancer (18) and ovarian cancer (26), respectively. Statistical analysis showed that TAP exhibited the closest relationship in ovarian cancer patients in whom the appearance of TAP and its high level were most prominent. The present preliminary study suggests the clinical usefulness of this protein as a clinical adjunct for the management of ovarian cancer.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
References (10)
- CA-125 in patients with endometriosis via openalex
- W1995214100 via openalex
- W2002660370 via openalex
- W2016682007 via openalex
- W2032566319 via openalex
- W2053423992 via openalex
- W2093452775 via openalex
- W2144849633 via openalex
- W2477008945 via openalex
- W6681625122 via openalex
Source provenance
- europepmc
- last seen: 2026-07-29T06:27:48.050232+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:11:49.821429+00:00
License: CC0
· commercial use OK